Expertise in
5
conditions

Dr. Laura L. Tenner

Hematology Oncology | Oncology
Unmc Physicians
Emile 42nd St, 
Omaha, NE 
Accepting New Patients
Offers Telehealth
Expertise in
5
conditions
Unmc Physicians
Emile 42nd St, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Laura Tenner is a Hematologist Oncology specialist and an Oncologist in Omaha, Nebraska. Dr. Tenner is highly rated in 5 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Neuroendocrine Tumor. Dr. Tenner is currently accepting new patients.

Her clinical research consists of co-authoring 21 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Bellevue Medical Center, LLC
The Nebraska Medical Center
Languages Spoken
English
American Sign Language
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 11 Less Insurance Carriers -

Locations

UNMC PHYSICIANS
Emile 42nd St, Omaha, NE 68198
Other Locations
UNMC PHYSICIANS
111 N 175th St, Omaha, NE 68118

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Other
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab
Study Phase: Phase 3
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, Carboplatin, Cisplatin, Etoposide, Temozolomide
Study Phase: Phase 2
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
Enrollment Status: Completed
Publish Date: May 01, 2024
Intervention Type: Other, Dietary supplement
Study Phase: Phase 2
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
Enrollment Status: Completed
Publish Date: July 03, 2023
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers
A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers
Enrollment Status: Unknown
Publish Date: February 16, 2022
Intervention Type: Drug
Study Drugs: Oraxol, Ramucirumab
Study Phase: Phase 1
View 8 Less Clinical Trials

21 Total Publications

Physical function in older adults receiving treatment: Correlates and predictors.
Physical function in older adults receiving treatment: Correlates and predictors.
Journal: Journal of geriatric oncology
Published: December 13, 2024
Similar Doctors
Julie M. Vose
Expertise in
34
conditions
Dr. Julie M. Vose
Hematology Oncology | Hematology | Oncology
Expertise in
34
conditions
Dr. Julie M. Vose
Hematology Oncology | Hematology | Oncology

Unmc Physicians

Emile 42nd St, 
Omaha, NE 
 (0.1 miles away)
402-559-4015
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Julie Vose is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Vose is highly rated in 34 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vose is currently accepting new patients.

Vijaya R. Bhatt
Expertise in
24
conditions
Dr. Vijaya R. Bhatt
Hematology Oncology | Hematology | Oncology
Expertise in
24
conditions
Dr. Vijaya R. Bhatt
Hematology Oncology | Hematology | Oncology

Unmc Physicians

Emile 42nd St, 
Omaha, NE 
 (0.1 miles away)
402-559-4015
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Vijaya Bhatt is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Bhatt is highly rated in 24 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bhatt is currently accepting new patients.

Expertise in
17
conditions
Dr. Luke T. Nordquist
Hematology Oncology | Oncology | Hematology
Expertise in
17
conditions
Dr. Luke T. Nordquist
Hematology Oncology | Oncology | Hematology

Urology Cancer Center PC

7500 Mercy Rd, 
Omaha, NE 
 (3.1 miles away)
402-398-6060
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Luke Nordquist is a Hematologist Oncology specialist and an Oncologist in Omaha, Nebraska. Dr. Nordquist is highly rated in 17 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, and Prostatectomy. Dr. Nordquist is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tenner's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile